CDK4 and liposarcoma: Furthermore, we believe that MDM2/CDK4 immunohistochemistry and FISH assay for MDM2 amplification are valuable tools for conclusively ruling out well-differentiated liposarcoma (WDLPS), particularly in diagnostically challenging cases (11).